Talk:Gilead Sciences

From Wikipedia, the free encyclopedia

Companies Portal

This article is within the scope of Companies WikiProject, a collaborative effort to improve Wikipedia's coverage of companies. If you would like to participate please visit the project page, where you can join the project and see a list of open tasks.

Start

This article has been rated as start-Class on the assessment scale.

???

This article has not yet received an importance rating assessment scale.

[edit] Allegations

Is there anything serious in the allegation that the bird flu "imminent pandemic" which has up to now killed some dozen people in about a decade is hyped in order to fill Rumsfeld's wallet? ROGNNTUDJUU! 22:54, 17 March 2006 (UTC)

What do you mean by "serious"? If you want to know whether this allegation can be backed up by cold, hard facts, then the answer is "No." --Felixkrull 18:22, 11 April 2006 (UTC)

Efavirenz is not a BMS product. It's produced by Merck.NYDCSP 22:04, 4 May 2007 (UTC)

Efavirenz is marketed in the USA by BMS under the trade name SUSTIVA [1]. It is marketed by one of the Merck subsidiaries in Europe. Gilead did a deal with BMS to combine efavirenz with Truvada to make Atripla in the USA [2], but does not have a similar agreement with Merck for the rest of the world. G716 19:49, 3 June 2007 (UTC)

[edit] Financial Highlights

Do we need this section?

Quickly out of date
Not straightforward to update in the format it is in
Info is already in the info box
More extensive and up to date info is easily available on the web
Not really encyclopedic content

G716 02:23, 23 June 2007 (UTC)

Removed the following outdated info:

Fiscal year 2005 (ended Dec. 31, 2005)[3][4]

                        GAAP                            NON-GAAP
Total Revenues          $2.028 billion                  $2.028 billion
Net Product Sales       $1.809 billion                  $1.809 billion
Total Expenses          $917.3 million                  $917.3 million
Net Income              $813.9 million                  $788.8 million
EPS                     $1.72 per diluted share         $1.66 per diluted share
Cash and Equivalents    $707.0 million                  

Stock Split (2-for-1)   September 2004 (most recent)

G716 06:04, 6 July 2007 (UTC)